首页> 美国卫生研究院文献>Molecules >Design Synthesis and SAR Study of Novel Trisubstituted Pyrimidine Amide Derivatives as CCR4 Antagonists
【2h】

Design Synthesis and SAR Study of Novel Trisubstituted Pyrimidine Amide Derivatives as CCR4 Antagonists

机译:新型三取代嘧啶酰胺衍生物作为CCR4拮抗剂的设计合成和SAR研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The design, synthesis and structure-activity relationship studies of some novel trisubstituted pyrimidine amide derivatives prepared as CCR4 antagonists are described. The activities of these compounds were evaluated by the CCR4-MDC chemotaxis inhibition assay. Compound >1, which we have previously reported as a potent antagonist of CCR4, was employed as the positive control. The results indicated that most of the synthesized compounds exhibited some chemotaxis inhibition activity against CCR4. Of these new compounds, compounds >6c, >12a and >12b, with IC50 values of 0.064, 0.077 and 0.069 μM, respectively, showed higher or similar activity compared with compound >1 (IC50 of 0.078 μM). These compounds provide a basis for further structural modifications. The systematic structure-activity relationship of these trisubstituted pyrimidine amide derivatives was discussed based on the obtained experimental data. The results from the SAR study may be useful for identifying more potent CCR4 antagonists.
机译:描述了一些新的作为CCR4拮抗剂制备的三取代嘧啶酰胺衍生物的设计,合成和结构活性关系。这些化合物的活性通过CCR4-MDC趋化抑制测定法评估。我们先前已报道过的化合物> 1 被用作CCR4的有效拮抗剂,被用作阳性对照。结果表明,大多数合成的化合物对CCR4表现出一定的趋化抑制活性。在这些新化合物中,化合物> 6c ,> 12a 和> 12b 的IC50值分别为0.064、0.077和0.069μM,显示出较高或相似的值与化合物> 1 相比具有更高的活性(IC50为0.078μM)。这些化合物为进一步的结构修饰提供了基础。基于获得的实验数据,讨论了这些三取代的嘧啶酰胺衍生物的系统结构-活性关系。 SAR研究的结果可能有助于确定更有效的CCR4拮抗剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号